Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysisRoberta Caputo, Michelino De Laurentiis, Francesco Pantano et al.|Frontiers in Oncology|2024Cited by 74
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort StudyFrancesca Carlino, Michele Orditura, Anna Diana et al.|Cancers|2022Cited by 36
Cancer in migrant populations: evidence from a regional oncology networkElisabetta Coppola, S. Pignata, Chiara D’Alessio et al.|BMC Public Health|2026Cited by 0